


- Important Announcement for Prescribers of Coumadin Therapy -

Medicare Approves PT/INR Self-Testing for AF & VTE patients –
INR@Home Service Now Available from Raytel

Medicare Part B now covers home PT/INR self-testing, including those with chronic atrial fibrillation (AF) and venous thromboembolism (VTE) that require oral anticoagulation therapy.

Medicare's decision to expand coverage was based upon ***published data confirming that PT/INR self-testing increases the likelihood of patients staying within their therapeutic range, and therefore reduces complications*** associated with INR levels outside of the prescribed range.

A meta-analysis of 14 randomized trials revealed significant reductions in thromboembolic events, major hemorrhage and death among patients who self-monitored their PT/INR. ¹



Raytel's ***INR@Home*** self-testing service meets the Medicare requirements and has already been prescribed by thousands of physicians seeking a better way to manage their Coumadin patients.

Service Benefits:

- ***It can increase time in therapeutic range, resulting in fewer Coumadin-related complications***
- ***It can improve your control over Coumadin therapy***
- ***It can result in a better quality of life for patients, fewer needle sticks, fewer lab visits***
- ***It can provide new billable procedures for your practice***

Raytel provides patients with FDA-cleared self-testing meters that are reliable and easy to use.



Our service is reimbursed by Medicare and a large number of commercial insurers.

For more information about Raytel's *INR@Home* PT/INR self-testing service, call 1-800-295-3530.

1 Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et. Al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006; 367:404-411.